摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

ethyl [3-({6-[2-(benzyloxy)phenyl]pyrimidin-4-yl}amino)benzyl]propylphosphinate | 1606169-34-9

中文名称
——
中文别名
——
英文名称
ethyl [3-({6-[2-(benzyloxy)phenyl]pyrimidin-4-yl}amino)benzyl]propylphosphinate
英文别名
6-(2-benzyloxyphenyl)-N-[3-[[ethoxy(propyl)phosphoryl]methyl]phenyl]pyrimidin-4-amine;N-[3-[[ethoxy(propyl)phosphoryl]methyl]phenyl]-6-(2-phenylmethoxyphenyl)pyrimidin-4-amine
ethyl [3-({6-[2-(benzyloxy)phenyl]pyrimidin-4-yl}amino)benzyl]propylphosphinate化学式
CAS
1606169-34-9
化学式
C29H32N3O3P
mdl
——
分子量
501.565
InChiKey
YYTWRZPWDPTELP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    651.200±65.00 °C(Press: 760.00 Torr)(predicted)
  • 密度:
    1.191±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    5.5
  • 重原子数:
    36
  • 可旋转键数:
    12
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.24
  • 拓扑面积:
    73.3
  • 氢给体数:
    1
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    ethyl [3-({6-[2-(benzyloxy)phenyl]pyrimidin-4-yl}amino)benzyl]propylphosphinate三甲基氯硅烷 、 potassium iodide 作用下, 以 氯仿 为溶剂, 反应 44.0h, 以45%的产率得到[3-({6-[2-(benzyloxy)phenyl]pyrimidin-4-yl}amino)benzyl]propylphosphinic acid
    参考文献:
    名称:
    Synthesis and Evaluation of Phosphorus Containing, Specific CDK9/CycT1 Inhibitors
    摘要:
    Although there is a significant effort in the design of a selective CDK9/CycT1 inhibitor, no compound has been proven to be a specific inhibitor of this kinase so far. The aim of this research was to develop novel and selective phosphorus containing CDK9/CycT1 inhibitors. Molecules bearing phosphonamidate, phosphonate, and phosphinate moieties were synthesized. Prepared compounds were evaluated in an enzymatic CDK9/CycT1 assay. The most potent molecules were tested in cell-based toxicity and HIV proliferation assays. Selectivity of shortlisted compounds against CDKs and other kinases was tested. The best compound was shown to be a highly specific, ATP-competitive inhibitor of CDK9/CycT1 with antiviral activity.
    DOI:
    10.1021/jm401742r
  • 作为产物:
    参考文献:
    名称:
    Synthesis and Evaluation of Phosphorus Containing, Specific CDK9/CycT1 Inhibitors
    摘要:
    Although there is a significant effort in the design of a selective CDK9/CycT1 inhibitor, no compound has been proven to be a specific inhibitor of this kinase so far. The aim of this research was to develop novel and selective phosphorus containing CDK9/CycT1 inhibitors. Molecules bearing phosphonamidate, phosphonate, and phosphinate moieties were synthesized. Prepared compounds were evaluated in an enzymatic CDK9/CycT1 assay. The most potent molecules were tested in cell-based toxicity and HIV proliferation assays. Selectivity of shortlisted compounds against CDKs and other kinases was tested. The best compound was shown to be a highly specific, ATP-competitive inhibitor of CDK9/CycT1 with antiviral activity.
    DOI:
    10.1021/jm401742r
点击查看最新优质反应信息

文献信息

  • Synthesis and Evaluation of Phosphorus Containing, Specific CDK9/CycT1 Inhibitors
    作者:Gábor Németh、Zoltán Greff、Anna Sipos、Zoltán Varga、Rita Székely、Mónika Sebestyén、Zsuzsa Jászay、Szabolcs Béni、Zoltán Nemes、Jean-Luc Pirat、Jean-Noël Volle、David Virieux、Ágnes Gyuris、Katalin Kelemenics、Éva Áy、Janos Minarovits、Susan Szathmary、György Kéri、László Őrfi
    DOI:10.1021/jm401742r
    日期:2014.5.22
    Although there is a significant effort in the design of a selective CDK9/CycT1 inhibitor, no compound has been proven to be a specific inhibitor of this kinase so far. The aim of this research was to develop novel and selective phosphorus containing CDK9/CycT1 inhibitors. Molecules bearing phosphonamidate, phosphonate, and phosphinate moieties were synthesized. Prepared compounds were evaluated in an enzymatic CDK9/CycT1 assay. The most potent molecules were tested in cell-based toxicity and HIV proliferation assays. Selectivity of shortlisted compounds against CDKs and other kinases was tested. The best compound was shown to be a highly specific, ATP-competitive inhibitor of CDK9/CycT1 with antiviral activity.
查看更多